Major Depressive Disorder Global Market Report 2025

Major depressive disorder, often referred to as clinical depression, is a mood disorder characterized by persistent feelings of sadness and a loss of interest in daily activities. These symptoms can disrupt essential aspects of life, such as sleep, appetite, and work performance, extending beyond typical mood fluctuations and profoundly affecting a person's thoughts, emotions, behavior, and overall well-being. Managing major depressive disorder involves various medical interventions to promote an individual's emotional health.

The key treatments for major depressive disorder encompass psychotherapy, medications, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and other therapeutic approaches. Psychotherapy involves the guidance of a trained mental health professional who assists individuals or groups in addressing emotional, psychological, and behavioral challenges. The diagnosis of major depressive disorder can be made through physical examinations, laboratory tests, psychiatric evaluations, references to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and other clinical methods. These interventions and evaluations are typically administered in various healthcare settings, including hospitals, clinics, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The major depressive disorder market research report is one of a series of new reports from The Business Research Company that provides major depressive disorder market statistics, including major depressive disorder industry global market size, regional shares, competitors with a major depressive disorder market share, detailed major depressive disorder market segments, market trends and opportunities and any further data you may need to thrive in the major depressive disorder industry. This major depressive disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The major depressive disorder market size has grown steadily in recent years. It will grow from $6.12 billion in 2024 to $6.26 billion in 2025 at a compound annual growth rate (CAGR) of 2.3%. The growth in the historic period can be attributed to pharmaceutical advances, mental health awareness, psychological therapies, public health initiatives.

The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $7.14 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to precision medicine, telepsychiatry and teletherapy, novel treatment modalities, global expansion of mental health services. Major trends in the forecast period include early intervention, peer support and online communities, holistic approaches, resilience and coping strategies.

The forecast of 3.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of rapid-acting antidepressants by inflating prices of patented formulations developed in Denmark and Belgium, resulting in delayed mental health interventions and higher psychiatric care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increase in cases of substance and alcohol abuse is anticipated to drive the growth of the major depressive disorder market. Substance and alcohol abuse refer to patterns of excessive and harmful use of substances, including alcohol, which can result in adverse physical, psychological, and social impacts. These issues often co-occur with major depressive disorder, with both conditions exacerbating each other and raising the risk of physical and mental harm. For example, in July 2024, a survey by the Substance Abuse and Mental Health Services Administration, a US-based health and human services department, revealed that 3.1% of individuals (8.9 million) misused opioids in 2023. Additionally, 21.8% of people aged 12 or older used marijuana, the most commonly used illicit drug, and 9.4% of individuals in the same age group vaped nicotine in the past month, an increase from 8.3% in 2022. Consequently, the rise in substance and alcohol abuse is contributing to the growth of the major depressive disorder market.

The rise in anxiety cases is expected to boost the growth of the major depressive disorder market. Anxiety is a natural response to stress, often bringing about feelings of fear, unease, and dread, and can lead to persistent and excessive worry about everyday events. Anxiety significantly affects major depressive disorder, contributing to nervousness, irritability, and difficulties with sleep and concentration. For instance, in May 2024, the American Psychiatric Association, a US-based nonprofit organization, reported that 43% of adults felt more anxious in 2024 compared to the previous year, up from 37% in 2023 and 32% in 2022. Therefore, the increasing prevalence of anxiety is driving the growth of the major depressive disorder market.

Prominent companies within the major depressive disorder market are concentrating on the development of pioneering products and obtaining regulatory approvals to gain a competitive edge. The approval of novel drugs for major depressive disorder treatment, such as VRAYLAR (cariprazine), is on the rise to address the demand for more effective and safer treatments. For instance, in December 2022, the US-based pharmaceutical company AbbVie Inc. received FDA (Food and Drug Administration) approval for VRAYLAR (cariprazine) as an adjunctive therapy alongside antidepressants for the treatment of major depressive disorder (MDD) in adults. VRAYLAR represents an innovative atypical antipsychotic medication that rebalances dopamine and serotonin levels in the brain. It stands as the first atypical antipsychotic to be approved for adjunctive major depressive disorder treatment, offering the convenience of a once-daily capsule.

In March 2022, AbbVie Inc., a US-based biopharmaceutical firm, acquired Syndesi Therapeutics SA for $130 million. This strategic acquisition is intended to bolster AbbVie Inc.'s neuroscience portfolio and expand its research and development capabilities in neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics SA, a Belgium-based biotechnology company, specializes in the development of therapeutic products for major depressive disorders and other neuropsychiatric conditions.

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the major depressive disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The major depressive disorder market consists of revenues earned by entities by providing services such as teletherapy, integrated care, cognitive behavioral therapy, interpersonal therapy, mindfulness-based therapy and residential treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The major depressive disorder market also includes sales of monoamine oxidase inhibitors, tricyclic antidepressants and mirtazapine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Major Depressive Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on major depressive disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for major depressive disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The major depressive disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments
• 2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis
• 3) By End-User: Clinics; Hospitals; Other End-Users
• Subsegments:
• 1) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Interpersonal Therapy (IPT); Dialectical Behavior Therapy (DBT); Psychodynamic Therapy
• 2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs); Atypical Antidepressants
• 3) Electroconvulsive Therapy (ECT): Unilateral ECT; Bilateral ECT; Modified ECT
• 4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS); Deep Transcranial Magnetic Stimulation (dTMS); Theta Burst Stimulation (TBS); Navigated Brain Stimulation (nTMS)
• 5) Other: Cognitive Behavioral Therapy (CBT); Psychodynamic Therapy; Interpersonal Therapy (IPT); Vagus Nerve Stimulation (VNS); Ketamine Therapy; Bright Light Therapy; Psychedelic-Assisted Therapy; Medication (Antidepressants)
• Companies Mentioned: Pfizer Inc.; Janssen Research And Development LLC; Merck and Co. Inc.; Novartis AG; Sanofi-Aventis US LLC; Bristol Myers Squibb Co.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Biogen Inc.; Otsuka Pharmaceuticals Co.Ltd.; Forest Laboratories Inc.; H. Lundbeck A/S; Richter Gedeon plc; Allergan plc; Neurocrine Biosciences Inc.; BlackThorn Therapeutics Inc.; Intra-Cellular Therapies Inc.; Axsome Therapeutics Inc.; Luye Pharma Group; BioLite Inc.; BrainsWay Ltd.; Neumora Therapeutics Inc.; Chase Therapeutics Corporation; SAGE Therapeutics Inc.; Arrivo Bioventures LLC; Relmada Therapeutics Inc.; Fabre-Kramer Pharmaceuticals Inc.; Vistagen Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.